Latest Headlines

Latest Headlines

Agendia scores $6.8M grant for study of molecular Dx technology in colorectal cancer

Agendia nabbed a $6.8 million grant from the European Commission to use its diagnostic technology to identify certain subtypes of colorectal cancer, a boost for the company as it forges ahead with its products and gains regulatory approval for its tests.

Agendia draws in $65M for cancer molecular Dx development

Agendia has pulled in $65 million in a private round of equity financing, with plans to use the massive cash infusion to advance and expand commercial development of its cancer-focused molecular diagnostic tests.

Agendia closes $23M Series E financing

Dutch molecular cancer diagnostic company Agendia has closed $23 million in series E financing. The round was led by an undisclosed family investment firm that provided approximately half of the

VC: Hyperion lands $40M in second round

Hyperion lands $40M in second round VENTURE CAPITALCOMPANY AMOUNT/ROUNDLEAD INVESTORSDESCRIPTION Hyperion Therapeutics South San

Molecular diagnostics firm gains $34M in VC

Amsterdam-based Agendia, a molecular diagnostics company, has raised $34 million in its fourth venture round, adding ING to its list of backers. Current investors Van Herk Biotech, Gilde Healthcare